<html><head><script id="decision-support-view" type="application/json">{
  "dsViewId": "Heng_score.v1",
  "language": {
    "originalLanguage": {
      "terminologyId": {
        "name": "ISO_639-1",
        "value": "ISO_639-1"
      },
      "codeString": "en"
    }
  },
  "decisionSupportViewDefinitions": {
    "sv": {
      "name": "Heng Score ",
      "description": "Prognos vid metastaserad njurcellscancer"
    },
    "en": {
      "name": "Heng Score",
      "description": "Prognosis in patients with metastatic renal cell carcinoma"
    }
  },
  "resourceDescription": {
    "originalAuthor": {
      "date": "2017-08-29",
      "name": "Syeeda S Farruque",
      "organisation": "Cambio Healthcare Systems",
      "email": "models@cambiocds.com"
    },
    "otherContributors": [
      "Dennis Forslund, Cambio Healthcare Systems"
    ],
    "lifecycleState": "Author draft",
    "details": {
      "sv": {
        "purpose": "Att med objektiva mått beräkna en prognos av överlevnadsgrad bland patienter med metastastisk njurcellscancer som genomgått VEGF-behandling.",
        "keywords": [
          "njurcellscancer",
          "vascular endothelial growth factor",
          "Heng score ",
          "VEGF",
          "njurcellscarcinom",
          "cancer",
          "onkologi"
        ],
        "use": "Använd som understöd vid stratifiering med avseende på överlevnadsgrad. Metoden är ännu inte validerad, men tre grupper med uppskattad medianöverlevnad har kunnat identifieras. Resultatet tolkas enligt:\n\n≤1p - gynnsam prognos: 43.2 månader\n2p - mellanliggande prognos: 22.5 månader\n≥3p - dålig prognos : 7.8 månader",
        "misuse": "Endast avsedd att utgöra understöd till klinisk bedömning då metoden ännu inte är validerad.",
        "copyright": "© Cambio Healthcare Systems"
      },
      "en": {
        "purpose": "Provides a prognostic assessment of overall survival in mRCC (metastatic renal cell carcinoma) patients treated with VEGF (vascular endothelial growth factor)–targeted therapy.",
        "keywords": [
          "metastatic renal cell carcinoma",
          "vascular endothelial growth factor",
          "Heng score for metastatic rcc prognosis"
        ],
        "use": "Helps to roughly stratify patients with mRCC into 3 survival prognostic groups.\n\nNo validated scroing systems available for the prediciton of mRCC survival but there are three survival groups with associated median survival: \n\nScore interpretation:\n\nScore \tPrognosis  \tMedian Survival\n≤1 \tFavorable  \t43.2 months\n2 \tIntermediate \t22.5 months\n≥3 \tPoor \t7.8 months\n",
        "misuse": "Must be used with sound clinical judgment as validation of the tool is still to be completed.",
        "copyright": "© Cambio Healthcare Systems"
      }
    },
    "otherDetails": {
      "references": "Ref. 1: Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C,McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study. JCO Dec 1, 2009:5794-5799; published online on October 13, 2009."
    }
  },
  "alertGuideIds": [],
  "executionGuideIds": [
    "Heng_mRCC.v1",
    "Heng_mRCC_Assessment.v1"
  ],
  "alertBindings": {},
  "termDefinitions": {
    "sv": {
      "id": "sv",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "Referenser"
        }
      }
    },
    "en": {
      "id": "en",
      "terms": {
        "vt0001": {
          "id": "vt0001",
          "text": "References"
        }
      }
    }
  },
  "resultTemplates": []
}</script></head><body></body></html>